Free Trial
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Price, News & Analysis

$27.72
-1.18 (-4.08%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
$27.54
$28.50
50-Day Range
$20.00
$29.01
52-Week Range
$7.38
$39.60
Volume
6,200 shs
Average Volume
49,258 shs
Market Capitalization
$83.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VTVT stock logo

About vTv Therapeutics Stock (NASDAQ:VTVT)

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

VTVT Stock Price History

VTVT Stock News Headlines

vTv Therapeutics Inc. (VTVT)
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
vTv Therapeutics Inc. Cl A
vTv Therapeutics Inc (VTVT)
vTv Therapeutics Inc - Ordinary Shares - Class A
See More Headlines
Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
5/26/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VTVT
Employees
16
Year Founded
N/A

Profitability

Net Income
$-20,250,000.00
Pretax Margin
-2,611.10%

Debt

Sales & Book Value

Annual Sales
$2.02 million
Book Value
$8.63 per share

Miscellaneous

Free Float
2,959,000
Market Cap
$83.44 million
Optionable
Not Optionable
Beta
0.52
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Paul J. Sekhri M.Sc. (Age 66)
    CEO, President & Chairman of the Board
    Comp: $650.91k
  • Mr. Steven Tuch M.B.A. (Age 55)
    Executive VP & CFO
    Comp: $465.25k
  • Dr. Carmen Valcarce Ph.D.
    Chief Scientific Officer & Executive VP
  • Ms. Elizabeth M. Keiley (Age 58)
    Executive VP & General Counsel
  • Mr. Richard S. Nelson (Age 54)
    Executive VP of Corporate Development & Director
    Comp: $201.08k
  • Dr. Thomas Strack M.D.
    Ph.D., Chief Medical Officer

VTVT Stock Analysis - Frequently Asked Questions

How have VTVT shares performed in 2024?

vTv Therapeutics' stock was trading at $11.50 at the beginning of 2024. Since then, VTVT shares have increased by 141.0% and is now trading at $27.72.
View the best growth stocks for 2024 here
.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our VTVT earnings forecast
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) announced its quarterly earnings data on Wednesday, March, 13th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter.

When did vTv Therapeutics' stock split?

Shares of vTv Therapeutics reverse split on the morning of Tuesday, November 21st 2023. The 1-40 reverse split was announced on Tuesday, November 21st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

vTv Therapeutics (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who are vTv Therapeutics' major shareholders?

vTv Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (3.23%). Insiders that own company stock include John A Fry and Ronald O Perelman.
View institutional ownership trends
.

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VTVT) was last updated on 5/27/2024 by MarketBeat.com Staff

From Our Partners